How many insider trades does FilingIQ track for ALDX?

FilingIQ tracks 139 Form 4 insider transactions for ALDX (Aldeyra Therapeutics, Inc.), covering filings from Jun 9, 2015 onwards. 4 of those were filed in the last 90 days.

Are ALDX insiders net buyers or net sellers?

Across the full Form 4 history for ALDX, 62 transactions (45%) were open-market purchases and 15 (11%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ALDX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ALDX in?

Aldeyra Therapeutics, Inc. (ALDX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $300.81M.

ALDX insider trading

NasdaqCM Healthcare

Aldeyra Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

139

Last 90 days

Buys / sells

45% / 11%

Market cap

$300.81M

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Company website: www.aldeyra.com

ALDX insider activity at a glance

FilingIQ has scored 139 insider transactions for ALDX since Jun 9, 2015. The most recent filing in our index is dated Mar 27, 2026.

Across the full history, 62 open-market purchases and 15 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ALDX insider trades is 51.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ALDX trades on FilingIQ Raw filings on SEC EDGAR

Latest ALDX Form 4 filings

Brady Todd C President and CEO

S Mar 12, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding ALDX

PERCEPTIVE ADVISORS LLC

$53.34M · 1.9% of AUM

Frequently asked

How many insider trades does FilingIQ track for ALDX?: FilingIQ tracks 139 Form 4 insider transactions for ALDX (Aldeyra Therapeutics, Inc.), covering filings from Jun 9, 2015 onwards. 4 of those were filed in the last 90 days.
Are ALDX insiders net buyers or net sellers?: Across the full Form 4 history for ALDX, 62 transactions (45%) were open-market purchases and 15 (11%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ALDX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ALDX in?: Aldeyra Therapeutics, Inc. (ALDX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $300.81M.

Methodology & sources

Every ALDX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.